Background It is not clear whether the administration of radioiodine provides any benefit to
patients with low-risk thyroid cancer after a complete surgical resection. The administration …

Background In patients with low-risk differentiated thyroid cancer undergoing thyroidectomy,
the postoperative administration of radioiodine (iodine-131) is controversial in the absence …

Background It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective
as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients with differentiated thyroid …

Background Radioactive iodine is commonly administered following thyroidectomy for
differentiated thyroid carcinoma to ablate the thyroid remnant. The optimal administered …

Management recommendations for differentiated thyroid cancer are evolving. Total
thyroidectomy is the backbone of curative-intent therapy, with radioiodine ablation (RAI) of …

Context: American Thyroid Association and European Thyroid Association guidelines
cannot recommend for or against radioactive iodine (RAI) ablation after surgery in low-risk …

Objectives Radioiodine ablation of thyroid tissue remains the cornerstone of treatment for
patients with differentiated thyroid carcinoma after thyroidectomy. Selecting an optimal dose …

Background: Radioactive iodine (RAI) remnant ablation has been used to eliminate normal
thyroid tissue and may also facilitate monitoring for persistent or recurrent thyroid carcinoma …

Post-surgical ablative iodine-131 therapy is recommended for all differentiated thyroid
cancer primary tumors> 1cm in diameter. Regarding smaller primary tumors, 131I ablation …

Background In ESTIMABL1, a randomised phase 3 trial of radioactive iodine (131 I)
administration after complete surgical resection in patients with low-risk thyroid cancer, 92 …